Skip to content

A Tube Feeding Study in Malnourished Population With Diabetes

A Prospective, Observational Study, of a High Calorie, High Protein Tube Feeding With Slow Release Carbohydrates and Monounsaturated Fatty Acids (MUFA), in a Malnourished Population With Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03766620
Enrollment
49
Registered
2018-12-06
Start date
2018-11-29
Completion date
2020-07-01
Last updated
2020-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition; Diabetes

Brief summary

This is a prospective, non-interventional, observational study. Malnourished subjects with diabetes, who are receiving a high calorie, high protein tube feeding with slow release carbohydrates and MUFA by their health care professional (HCP) per standard of care will be enrolled into the study.

Interventions

None listed

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Voluntarily signed and dated an informed consent form, approved by an Independent Ethics Committee, prior to any participation in the study * Considered malnourished, or at risk for malnutrition * Diagnosed with diabetes mellitus type 1 or 2 and treated with oral hypoglycemic medications and/or exogenous insulin * Conforms to the requirements set forth on the study product label * Under the care of a health care professional for malnutrition and has recently been prescribed tube feeding as a sole-source of nutrition by their health care professional * Free living, residing in a nursing home or admitted to the hospital and has anticipated length of hospital stay \> 3 days and \< 12 days

Exclusion criteria

* Severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures * Cannot safely consume the study product, or known to be allergic or intolerant to any ingredient found in the study product * Renal or liver failure * Participates in another study that has not been approved as a concomitant study by AN

Design outcomes

Primary

MeasureTime frameDescription
Body Weight ChangeBaseline to Study Exit Week 12Measured in Kg

Secondary

MeasureTime frameDescription
Malnutrition Universal Screening Tool (MUST)Baseline to Study Exit Week 12HCP completed screening tool
Subjective Global Assessment (SGA)Baseline to Study Exit Week 12HCP completed nutrition assessment
Quality of life (EuroQol EQ-5D-5L)Baseline to Study Exit Week 12Subject rated health state of 5 dimensions. Each dimension has 5-levels scaled in negative direction resulting in an overall 5-digit number describing the health state; EQ VAS Score 0-100 points scaled in positive direction
Glucose controlBaseline to Study Exit Week 12HbA1c levels
Product ComplianceBaseline to Study Exit Week 12Product consumption diary
Albumin LevelsBaseline to Study Exit Week 12Nutrition status parameter collected per standard of care
Body Mass IndexBaseline to Study Exit Week 12BMI calculated Weight (kg)/Height (m)2

Other

MeasureTime frameDescription
FunctionalityBaseline to Study Exit Week 12Barthel Index of Activities of Daily Living; Subject completed assessment of 10 functions; Sum of scores range from 0-20 scaled in positive direction
Physician Product SatisfactionBaseline to Study Exit Week 12Physician Completed Questionnaire; 3 to 5 category responses scaled in negative direction

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026